3-Month Safety Data Outcomes from a Phase 3 Study of AZR-MD-001 0.5% (ASTRO) for the Treatment of Dry Eye Disease and Signs of Meibomian Gland Dysfunction

AZR-MD-001 - Azura Ophthalmics

David Wirta5; Christopher Starr1; Preeya Gupta2; Sumit Garg3; Yair Alster4; Charles Bosworth4

May 8, 2026